European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
MORRISTOWN, N.J., March 15, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that the Company will report financial results for the fourth quarter and year ended December 31, 2016, after the market close on Tuesday, March 28, 2017. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
| Date: | Tuesday, March 28 | |||||
| Time: | 4:30 PM ET | |||||
| Toll free (U.S.): | 888-576-4382 | |||||
| International: | 719-457-2735 | |||||
| Conference ID: | 4228557 | |||||
| Webcast: | http://public.viavid.com/index.php?id=123412 | |||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its integrated Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT Investor Relations Matthew P. Duffy, 212-915-0685 LifeSci Advisors, LLC [email protected]
